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background:  High platelet reactivity (HPR) has been associated with increased stent thrombosis (ST) and myocardial infarction (MI) 
after percutaneous intervention (PCI). However, given the low rate of adverse events in non-acute coronary syndrome (ACS) (ie, stable) 
patients, the role of HPR testing in this population remains uncertain.
methods:  ADAPT-DES was a prospective, multicenter registry of patients successfully treated with one or more drug-eluting stents. Non-
ACS pts were classified in two groups according to the complexity of the PCI (complex PCI was defined as ≥3 stents implanted, use of 
rotational atherectomy, saphenous vein graft, bifurcation with two stents implanted, and left main PCI) and stratified according to platelet 
reactivity (low: PRU <208 vs. high: PRU ≥208). Two-year outcomes were compared.
results:  Among a total of 8,582 pts enrolled, 4,103 (47.8%) were non-ACS pts, with 1,241 (30.2%) who underwent complex PCI. Two-
year adverse events were the highest in patients with complex PCI and PRU≥208, and the lowest in patients with non-complex PCI and 
PRU <208 (Table). After multivariable analysis, adjusting for PRU, complex PCI was an independent predictor of ARC-defined ST (HR [95% 
CI] 5.59 [2.12,14.74] p=0.0005), MI (HR 1.55 [1.07, 2.25], p=0.02), death/MI (HR 1.38 [1.04, 1.82], p=0.03), and MACE (HR 1.83 [1.44, 
2.31], p<0.0001), while PRU was not.
Conclusion:  Stable patients undergoing complex PCI are at high-risk of adverse events and may benefit of a more potent P2Y12 
inhibition.
Two-Year Outcomes According to Percutaneous Coronary Intervention Complexity and Platelet Reactivity
Low Platelet Reactivity (PRU <208) High Platelet Reactivity (PRU ≥208)
Stable
No Complex 
PCI
(N=1718)
Stable
Complex PCI
(N=753)
p Value
Stable
No Complex 
PCI
(N=1144)
Stable
Complex PCI
(N=488)
p Value p Trend†
Major adverse cardiac events 6.4% (105) 16.1% (119) <0.0001 9.1% (98) 17.6% (83) <0.0001 <0.0001
Target vessel failure 10.8% (177) 21.5% (159) <0.0001 14.7% (160) 23.9% (113) <0.0001 <0.0001
Death/myocardial infarction 5.0% (82) 9.2% (68) <0.0001 7.3% (80) 12.4% (59) <0.0001 <0.0001
Death 2.9% (47) 4.3% (31) 0.21 4.5% (49) 4.9% (23) 0.03 0.02
Cardiac 1.4% (23) 2.8% (20) 0.15 2.3% (25) 2.6% (12) 0.005 0.03
Myocardial infarction 2.5% (40) 6.0% (44) <0.0001 3.6% (39) 8.2% (39) <0.0001 <0.0001
ARC-defined ST (definite/
probable)* 0.2% (3) 1.1% (8) 0.06 0.5% (5) 1.7% (8) 0.0007 <0.0001
ARC = Academic Research Consortium; MACE = major adverse cardiovascular event; MI = myocardial infarction; PCI = percutaneous 
coronary intervention; ST = stent thrombosis; TVF = target vessel failure.
*Target lesion stent thrombosis. †p Trend for 4-group comparison
